Pulmonx Corporation (NASDAQ: LUNG) Q2 2025 Earnings | 08/01/2025

About this video

Pulmonx Corporation reported solid second quarter 2025 results, with revenue rising 15% year-over-year to $23.9 million, narrowly exceeding consensus expectations. The company’s international sales led growth, surging 32% over Q2 2024, while U.S. revenue rose only 6% amid persistent operational headwinds in domestic commercialization. Pulmonx’s flagship Zephyr Endobronchial Valve continued to see robust global adoption, supported by expanded treatment guidelines and growing international reimbursement. Operational focus included the training of 26 new physicians and the opening of 12 new screening facilities in Q2, aiming to improve patient access and raise conversion rates. Gross profit for the quarter was $17.2 million, up from $15.3 million in Q2 2024, although gross margin slipped to 72% from 74% due to a larger share of revenue from lower-margin international markets. Operating expenses rose modestly to $32 million, reflecting investments in marketing, physician outreach, and infrastructure. The company posted a net loss of $15.2 million, or $(0.38) per share, a slight improvement over the year-ago quarter’s $(0.39) per share loss. Adjusted EBITDA loss for Q2 was $8.4 million. Management revised full-year 2025 revenue guidance downward to $90–92 million from the previous $96–98 million forecast, citing slower-than-expected U.S. patient conversion despite early success in direct-to-patient campaigns and ongoing bottlenecks at interventional pulmonology centers. Cash and equivalents stood at $84.2 million as of June 30, down from $88.7 million at the end of Q1 2025, as Pulmonx continues to pursue operational discipline and global market expansion. A focal point for the second half of 2025 includes accelerating U.S. adoption, maintaining strong international momentum, and preparing for next-generation product launches. About Inside Ticker: For more expert analysis and real-time updates on Pulmonx Corporation (NASDAQ: LUNG) and other market movers, follow Inside Ticker and visit http://www.insideticker.com/ for in-depth reports, financial insights, and the latest news on leading companies. #Pulmonx #LUNG #Q22025 #Earnings #FinancialResults #RevenueGrowth #ZephyrValve #Emphysema #GrossMargin #InternationalExpansion #NetLoss #EBITDA #MedicalDevices #Innovation #PatientEngagement #PhysicianTraining #OperationalExcellence #ClinicalAdoption #CashFlow #2025Outlook #InsideTicker